TABLE 1.
Clinical characteristics and their association with OS in NSCLC patients treated with ICI.
| Patient characteristics | Median (SD) or Number (%) | Univariate | Multivariate | ||
|---|---|---|---|---|---|
| HR (95%CI) | p-Value | HR (95%CI) | p-Value | ||
| Age (years), Median (SD) | 69 (9.8) | 1.01 (0.99–1.04) | 0.330 | ||
| Sex, N (%) | |||||
| Male | 79 (74.5%) | 1 | 1 | ||
| Female | 27 (25.5%) | 1.94 (1.15–3.18) | 0.014 | 2.10 (1.01–4.19) | 0.048 |
| PS, N (%) | |||||
| 0–1 | 91 (85.8%) | 1 | 1 | ||
| 2–3 | 15 (14.2%) | 2.52 (1.31–4.51) | 0.007 | 2.04 (1.02–3.84) | 0.045 |
| Smoking, N (%) | |||||
| Ever | 84 (79.2%) | 1 | 1 | ||
| Never | 22 (20.8%) | 0.58 (0.35–1.03) | 0.062 | 1.13 (0.53–2.48) | 0.756 |
| Histology, N (%) | |||||
| Non-Squamous | 71 (67.0%) | 1 | |||
| Squamous | 35 (33.0%) | 0.93 (0.54–1.53) | 0.771 | ||
| Driver mutation, N (%) | |||||
| Wild type | 87 (82.1%) | 1 | |||
| EGFR, ALK, ROS1 | 19 (17.9%) | 0.99 (0.52–1.76) | 0.971 | ||
| PD-L1 expression, N (%) | |||||
| 0%–49% | 56 (52.8%) | 1 | |||
| 50%–100% | 34 (32.1%) | 0.80 (0.45–1.38) | 0.426 | ||
| NA | 16 (15.1%) | ||||
| PD-1/PD-L1 inhibitor, N (%) | |||||
| Pembrolizumab | 64 (60.4%) | 1 | 1 | ||
| Nivolumab | 24 (22.6%) | 0.72 (0.42–1.28) | 0.254 | 0.90 (0.43–1.89) | 0.790 |
| Atezolizumab | 18 (17.0%) | 0.36 (0.15–0.82) | 0.013 | 0.48 (0.18–1.15) | 0.101 |
| Combination chemotherapy, N (%) | |||||
| (−) | 55 (51.9%) | 1 | 1 | ||
| (+) | 51 (48.1%) | 0.63 (0.38–1.01) | 0.056 | 0.94 (0.50–1.83) | 0.862 |
| Treatment line, N (%) | |||||
| 1 | 57 (53.8%) | 1 | 1 | ||
| >2 | 49 (46.2%) | 1.58 (0.98–2.56) | 0.061 | 1.58 (0.84–2.95) | 0.155 |
| IL-6 (pg/mL), Median (SD) | 15.3 (33.9) | 1.26 (0.98–1.56) | 0.053 | 1.34 (1.05–1.68) | 0.012 |
| sIL-6R (pg/mL), Median (SD) | 30927.7 (11303.1) | 0.98 (0.76–1.26) | 0.882 | ||
| sgp130 (pg/mL), Median (SD) | 151388.7 (49732.4) | 0.99 (0.77–1.26) | 0.934 | ||
Categorical variables are presented as the distribution of corresponding patient numbers. Continuous variables are presented as median and standard deviation (SD) values. Univariate and multivariate analysis was performed using the Cox proportional hazards model for overall survival (OS). Abbreviations: hazard ratio (HR), confidence interval (CI), performance status (PS), epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), not assessed (NA), soluble IL-6R (sIL-6R), soluble gp130 (sgp130).